BDBM100827 US8507533, 138::US8507533, 151::US8507533, 374
SMILES: Cc1cc(OC(C2CCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cc(cn1)C(F)(F)F
InChI Key: InChIKey=CLTIPYUCTVVDMY-UHFFFAOYSA-N
Data: 2 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glucagon (Homo sapiens (Human)) | BDBM100827 (US8507533, 138 | US8507533, 151 | US8507533, 374) | Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 5.75 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Glucagon (Homo sapiens (Human)) | BDBM100827 (US8507533, 138 | US8507533, 151 | US8507533, 374) | Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 20.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair |